Recent Research Analysts’ Ratings Updates for Kiniksa Pharmaceuticals International (KNSA)

A number of research firms have changed their ratings and price targets for Kiniksa Pharmaceuticals International (NASDAQ: KNSA):

• 7/30/2026 – Kiniksa Pharmaceuticals International was downgraded by Zacks Research from “strong-buy” to “hold”.
• 7/30/2026 – Kiniksa Pharmaceuticals International had its price target raised by The Goldman Sachs Group, Inc. from $75.00 to $90.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Kiniksa Pharmaceuticals International was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 7/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by JPMorgan Chase & Co. from $72.00 to $107.00. They now have an “overweight” rating on the stock.
• 7/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by Canaccord Genuity Group Inc. from $64.00 to $98.00. They now have a “buy” rating on the stock.
• 7/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wedbush from $72.00 to $99.00. They now have an “outperform” rating on the stock.
• 7/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by Citigroup Inc. from $60.00 to $100.00. They now have a “buy” rating on the stock.
• 7/23/2026 – Kiniksa Pharmaceuticals International had its price target raised by The Goldman Sachs Group, Inc. from $60.00 to $75.00. They now have a “buy” rating on the stock.
• 7/13/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wells Fargo & Company from $57.00 to $74.00. They now have an “overweight” rating on the stock.
• 7/12/2026 – Kiniksa Pharmaceuticals International was downgraded by Wall Street Zen from “strong-buy” to “buy”.
• 6/29/2026 – Kiniksa Pharmaceuticals International had its price target raised by Wedbush from $59.00 to $72.00. They now have an “outperform” rating on the stock.
• 6/23/2026 – Kiniksa Pharmaceuticals International was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.
• 6/17/2026 – Kiniksa Pharmaceuticals International was upgraded by Zacks Research from “hold” to “strong-buy”.

Insider Transactions at Kiniksa Pharmaceuticals International

In other Kiniksa Pharmaceuticals International news, Director G Bradley Cole sold 3,673 shares of Kiniksa Pharmaceuticals International stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the completion of the sale, the director directly owned 11,672 shares of the company’s stock, valued at $950,450.96. The trade was a 23.94% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 51.98% of the stock is currently owned by company insiders.

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.